Miltefosine was the first oral compound approved for visceral leishmaniasis chemotherapy, and its efficacy against Leishmania donovani has been well documented. Leishmania amazonensis is the second most prevalent species causing cutaneous leishmaniasis and the main etiological agent of diffuse cutaneous leishmaniasis in Brazil. Driven by the necessity of finding alternative therapeutic strategies for a chronic diffuse cutaneous leishmaniasis patient, we evaluated the susceptibility to miltefosine of the Leishmania amazonensis line isolated from this patient, who had not been previously treated with miltefosine. In vitro tests against promastigotes and intracellular amastigotes showed that this parasite isolate was less susceptible to miltefosine than L. amazonensis type strains. Due to this difference in susceptibility, we evaluated whether genes previously associated with miltefosine resistance were involved. No mutations were found in the miltefosine transporter gene or in the Ros3 or pyridoxal kinase genes. These analyses were conducted in parallel with the characterization of L. amazonensis mutant lines selected for miltefosine resistance using a conventional protocol to select resistance in vitro, i.e., exposure of promastigotes to increasing drug concentrations. In these mutant lines, a single nucleotide mutation G852E was found in the miltefosine transporter gene. In vivo studies were also performed to evaluate the correlation between in vitro susceptibility and in vivo efficacy. Miltefosine was effective in the treatment of BALB/c mice infected with the L. amazonensis type strain and with the diffuse cutaneous leishmaniasis isolate. On the other hand, animals infected with the resistant line bearing the mutated miltefosine transporter gene were completely refractory to miltefosine chemotherapy. These data highlight the difficulties in establishing correlations between in vitro susceptibility determinations and response to chemotherapy in vivo. This study contributed to establish that the miltefosine transporter is essential for drug activity in L. amazonensis and a potential molecular marker of miltefosine unresponsiveness in leishmaniasis patients.
Trans R Soc Trop Med Hyg. 1980;74(2):243-52
[PMID:
7385303]
Br J Dermatol. 2007 Jun;156(6):1328-35
[PMID:
17441955]
Genome Res. 2011 Dec;21(12):2129-42
[PMID:
22038252]
Mem Inst Oswaldo Cruz. 2011 Jun;106(4):475-8
[PMID:
21739037]
Trop Med Int Health. 2010 Jan;15(1):68-76
[PMID:
19874570]
PLoS One. 2013;8(1):e55604
[PMID:
23383240]
Lancet. 2005 Oct 29-Nov 4;366(9496):1561-77
[PMID:
16257344]
Emerg Infect Dis. 2012 Apr;18(4):704-6
[PMID:
22469394]
Biol Res. 1993;26(1-2):159-66
[PMID:
7545499]
Acta Trop. 2002 Feb;81(2):151-7
[PMID:
11801222]
Microbes Infect. 2007 Apr;9(4):529-35
[PMID:
17350306]
Int J Antimicrob Agents. 2012 Apr;39(4):326-31
[PMID:
22226653]
J Antimicrob Chemother. 2004 Oct;54(4):704-10
[PMID:
15329361]
Clin Infect Dis. 2004 May 1;38(9):1266-72
[PMID:
15127339]
Antimicrob Agents Chemother. 2009 Feb;53(2):835-8
[PMID:
19015344]
PLoS Negl Trop Dis. 2012;6(5):e1664
[PMID:
22666513]
PLoS Negl Trop Dis. 2012 Jan;6(1):e1469
[PMID:
22292094]
J Cell Sci. 1989 Jun;93 ( Pt 2):363-74
[PMID:
2613764]
Antimicrob Agents Chemother. 2003 Aug;47(8):2397-403
[PMID:
12878496]
J Infect Dis. 2006 Oct 15;194(8):1168-75
[PMID:
16991093]
N Engl J Med. 1999 Dec 9;341(24):1795-800
[PMID:
10588964]
J Microbiol Methods. 2013 May;93(2):95-101
[PMID:
23466934]
J Biol Chem. 2003 Dec 12;278(50):49965-71
[PMID:
14514670]
J Biol Chem. 2006 Aug 18;281(33):23766-75
[PMID:
16785229]
Parasitol Today. 1997 Feb;13(2):80-2
[PMID:
15275128]
PLoS Negl Trop Dis. 2012;6(2):e1512
[PMID:
22348164]
PLoS One. 2012;7(5):e35671
[PMID:
22693548]
N Engl J Med. 2002 Nov 28;347(22):1739-46
[PMID:
12456849]
J Biol Chem. 1987 Apr 25;262(12):5890-8
[PMID:
3571240]
DNA Res. 2013 Dec;20(6):567-81
[PMID:
23857904]
Diagn Microbiol Infect Dis. 2003 Sep;47(1):349-58
[PMID:
12967749]
PLoS Negl Trop Dis. 2013 Apr 25;7(4):e2179
[PMID:
23638200]
Exp Parasitol. 2013 Sep;135(1):36-41
[PMID:
23747751]
Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 Oct 1;62(Pt 10):1006-9
[PMID:
17012797]
Int J Antimicrob Agents. 2007 Sep;30(3):229-35
[PMID:
17628445]
Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S26-33
[PMID:
16730038]
Parasitol Res. 2014 May;113(5):1875-81
[PMID:
24615359]
Am J Trop Med Hyg. 2005 Aug;73(2):272-5
[PMID:
16103588]
Bioinformatics. 2007 May 15;23(10):1289-91
[PMID:
17379693]
